EDIT

Editas Medicine, Inc.

5.30 USD
-0.42 (-7.34%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Editas Medicine, Inc. stock is up 5.16% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 8 July’s closed higher than June. In the last 5 Unusual Options Trades, there were 3 PUTs, 2 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
21 May 17:58 19 Jul, 2024 10.00 PUT 100 0
12 Jun 13:50 21 Jun, 2024 6.00 CALL 1143 534
17 Jun 14:54 15 Nov, 2024 7.50 PUT 100 38
10 Jul 18:33 09 Aug, 2024 5.00 PUT 568 1
11 Jul 13:30 16 Jan, 2026 2.50 CALL 100 135

About Editas Medicine, Inc.

Editas Medicine, Inc. focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.